In order to ensure reliable data on the effectiveness of drugs used in clinical trials, good clinical practice (GCP) was established, first in the United States and then in Europe. Clinical quality assurance (CQA), including company audits and Food and Drug Administration (FDA) inspections of investigators, monitors, and sponsors to ensure compliance with GCP, followed. This paper discusses the components, benefits, and future of clinical quality assurance.
Proposed Establishment of Regulations on Obligations of Sponsors and Monitors.Federal Register. 1977; Part IV, Vol. 42, No. 187.
2.
GerlisL. Good Clinical Practice in clinical research. Lancet. 1989;i:1008–1009.
3.
KendallMJ. Taking a beta-blocker to Washington. In BerdJWoodJFBWonkCAS, eds. Modern Aspects of Beta-blocker Therapy. Wehr, Germany: Ciba Geigy Pharmaceuticals; 1987.
4.
The rules governing medicinal products in the European Community—Volume III (Addendum) Good Clinical Practice for Trials on Medicinal Products in the European Community. (For implementation on 1 July 1991) (Final Version (111/3976/88-EN)). Brussels, Belgium: Commission of the European Communities; 1988.
5.
EC GCP—clinical expert's role. SCRIP. No. 1704, March 27 1992, p. 3.
